4528

ONO PHARMACEUTICAL CO., LTD.

小野薬品工業株式会社
Healthcare · Drug Manufacturers - General
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
← Companies
Price
¥2,392
Market Cap
¥1.1T
Ent. Value
¥1.1T
Net Cash
¥69.6B
Shares Out.
469.8M
P / E
22.5×
EV / EBIT
17.6×
P / Book
—
P / NCAV
6.27×
Div. Yield
3.34%
Financials
Metric FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥486.9B ¥502.7B ¥447.2B ¥361.4B
Cost of Sales ¥147.9B ¥127.1B ¥110.1B ¥93.5B
Gross Profit ¥338.9B ¥375.5B ¥337.1B ¥267.9B
SG&A ¥125.7B ¥100.3B ¥89.5B ¥77.1B
Operating Income ¥59.7B ¥159.9B ¥142.0B ¥103.2B
Non-Operating Income ¥4.8B ¥4.0B ¥2.5B ¥2.7B
Non-Operating Expenses ¥5.3B ¥229M ¥913M ¥874M
Pre-tax Income ¥59.3B ¥163.7B ¥143.5B ¥105.0B
Net Income (owners) ¥50.0B ¥128.0B ¥112.7B ¥80.5B
Minority Interest ¥119M ¥62M ¥190M ¥166M
Comprehensive Income ¥28.9B ¥137.9B ¥115.8B ¥79.6B
EBITDA ¥86.6B ¥178.1B ¥159.4B ¥120.9B
EPS ¥106.55 ¥266.61 ¥230.85 ¥162.19
Shares Outstanding 469.8M 469.7M 488.4M 488.3M
Shares Issued (total) 498.7M 498.7M 517.4M 528.3M
Treasury Shares 28.9M 29.0M 29.0M 40.0M